U.S. to tighten disclosure obligations of foreign listed companies, targeting China; China to allow local investors to invest more in overseas assets under QDII; and EU issues measures to restrict Chinese medical device manufacturers from accessing public procurement contracts
Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
CATL and Ant Group’s planned listings could break recent HK IPO records; The lowering of U.S. drug prices will impact Chinese drugmakers; and U.S. House passes sanctions bill targeting trade secret theft by China.
China eases cross-border data transfer restrictions for financial institutions; Trade war prompts plan to open up service sector; and new law firm anti-money laundering regulations to align with international standards
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Hong Kong stock market rebounds when Chinese government halts Swiss listings; China backs AI with government investment fund; and China’s Supreme People’s Court further protects intellectual property rights in apple plant varieties.
